Peptide Research Collection Library
Explore the compound
Quick Facts
Mechanism of Action
Tirzepatide is a synthetic peptide that acts as a dual GIP and GLP-1 receptor agonist. It is designed with fatty-diacid modification to extend duration of action. Its mechanism supports incretin signaling, glucose regulation, satiety, and body-weight reduction pathways.
Mechanism of Action: supports incretin signaling, glucose regulation, satiety, and body-weight reduction pathways.
- Delivers strong body-weight and waist-circumference reductions in obesity clinical trials [1].
- Improves A1C and fasting-glucose control through dual GIP/GLP-1 activity [1].
- Supports appetite regulation and improved satiety in metabolic research [3].
- Associated with improvements in cardiometabolic markers such as triglycerides, blood pressure, and insulin sensitivity [1].
- Backed by official trial registry records across obesity, diabetes, and related metabolic endpoints [2].
Research Applications & Context
Community-reported protocol schedules.
Research Dosage Information
Reported research quantities and their source context. These are not recommendations, and source status varies.
Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.
Community report 1 · Weeks 1-4: 2.5 mg Once weekly. Weeks 1-4. Community report 1 · Weeks 5-8: 5 mg Once weekly. Weeks 5-8. Community report 1 · Weeks 9-12: 7.5 mg Once weekly. Weeks 9-12. Community report 1 · Weeks 13-16: 10 mg Once weekly. Weeks 13-16. Community report 1 · Weeks 17-20: 12.5 mg Once weekly. Weeks 17-20. Community report 1 · Weeks 21+: 15 mg Once weekly. Weeks 21+. Community report 2 · Phase 1 – Initiation: 2.5 mg Once weekly. Weeks 1-4. Community report 2 · Phase 2 – 5 mg step: 5 mg Once weekly. Weeks 5-8. Community report 2 · Phase 3 – Mid escalation: 7.5 mg Once weekly. Weeks 9-12. Community report 2 · Phase 4 – 10 mg step: 10 mg Once weekly. Weeks 13-16. Community report 2 · Phase 5 – High escalation: 12.5 mg Once weekly. Weeks 17-20. Community report 2 · Phase 6 – Maximum dose: 15 mg Once weekly. Weeks 21+.
| Phase | Reported Amount | Frequency | Draw Units | Cycle | Notes | Calculator |
|---|---|---|---|---|---|---|
| Community report 1 · Weeks 1-4 | 2.5 mg | Once weekly | Select a vial | Weeks 1-4 | Community-reported protocol. | |
| Community report 1 · Weeks 5-8 | 5 mg | Once weekly | Select a vial | Weeks 5-8 | Community-reported protocol. | |
| Community report 1 · Weeks 9-12 | 7.5 mg | Once weekly | Select a vial | Weeks 9-12 | Community-reported protocol. | |
| Community report 1 · Weeks 13-16 | 10 mg | Once weekly | Select a vial | Weeks 13-16 | Community-reported protocol. | |
| Community report 1 · Weeks 17-20 | 12.5 mg | Once weekly | Select a vial | Weeks 17-20 | Community-reported protocol. | |
| Community report 1 · Weeks 21+ | 15 mg | Once weekly | Select a vial | Weeks 21+ | Community-reported protocol. | |
| Community report 2 · Phase 1 – Initiation | 2.5 mg | Once weekly | Select a vial | Weeks 1-4 | Community-reported protocol. | |
| Community report 2 · Phase 2 – 5 mg step | 5 mg | Once weekly | Select a vial | Weeks 5-8 | Community-reported protocol. | |
| Community report 2 · Phase 3 – Mid escalation | 7.5 mg | Once weekly | Select a vial | Weeks 9-12 | Community-reported protocol. | |
| Community report 2 · Phase 4 – 10 mg step | 10 mg | Once weekly | Select a vial | Weeks 13-16 | Community-reported protocol. | |
| Community report 2 · Phase 5 – High escalation | 12.5 mg | Once weekly | Select a vial | Weeks 17-20 | Community-reported protocol. | |
| Community report 2 · Phase 6 – Maximum dose | 15 mg | Once weekly | Select a vial | Weeks 21+ | Community-reported protocol. |
Dosing Protocol & Schedule
Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.
| Period | Research Dose | Frequency | Total Injections | Total amount | Volume per entry | U-100 equivalent |
|---|
Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.
Plan a Regimen Schedule
Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.
Reconstitution Calculator
Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.
Reconstitution Reference Chart
Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.
| Example volume | Calculated concentration | Calculator |
|---|---|---|
| 1 mL | — | |
| 2 mL | — | |
| 3 mL | — | |
| 4 mL | — | |
| 5 mL | — |
Choose a compatible dry vial to see reference concentrations.
Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.
Supplies Needed — Estimate
Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.
Select a compatible vial and volume below to view quantities.
Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.
Published References (1 identified)
A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.
- Tirzepatide Once Weekly for the Treatment of Obesity (2022) View source ↗ The New England Journal of Medicine — randomized trial · Publisher or publication identifier recorded; claim verification separate
Research indexes & other source links
Searches, registries and unverified source records are discovery resources, not verified published studies.
- PubMed.gov biomedical literature: Tirzepatide View source ↗ PubMed index/search · Source link recorded; claim verification separate
- ClinicalTrials.gov study registry: Tirzepatide View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
- NIH/NCBI all-databases search: Tirzepatide View source ↗ NCBI database/search · Source link recorded; claim verification separate
- PubChem / NIH compound record search: Tirzepatide View source ↗ PubChem database/search · Source link recorded; claim verification separate
- MedlinePlus / NIH patient drug information search: Tirzepatide View source ↗ Web reference · Source link recorded; claim verification separate
